Reen fluorescent protein was fused in framed with the UL35 open

Reen fluorescent protein was fused in framed with the UL35 open reading frame generating K26GFP virus whose capsids expressTin Oxide Nanowires as Anti-HSV AgentsFigure 5. SnO2 treatment reduces glycoprotein mediated cell-to-cell fusion. Two populations of cells were generated to determine the effect of SnO2 treatment on cell fusion. Effector cells were 25033180 transfected with plasmids gB, gD, gH, gL and T7. Target cells were transfected with gD, receptor Nectin-1 and a luciferase expressing plasmid under the control of a T7 promoter. Target and Effector cells were mixed together at a 1:1 ratio. Luciferase activity was determined in the presence of firefly luciferase, allowing the measurement of relative light units (RLU). CHO-K1 cells were either mock treated or treated with SnO2. As a negative control, effector cells lacking gB were mixed with the target cells. doi:10.1371/journal.pone.0048147.gGFP [21]. Virus stocks were propagated and tittered on Vero cells and stored at 280uC.Cytotoxicity AssayTo determine the effect of SnO2 nanowires on the viability of HCE cells an MTS cytotoxicity assay was performed after 24 hours of SnO2 treatment. Briefly, HCE cells were seeded at a density of 26104 in a 96-well plate and incubated until confluent. SnO2 was then brought into suspension in MEM media at concentrations of [3000, 1500, 750, 375, 187, 93, 47, or 0] mg/ ml and added to the appropriate wells. 24 hours later the cell viability was analyzed by a chromogenic kit (CellTiter Aqueous96; Promega, Madison, WI, USA). Colorimetric detection was measured by a micro-pate reader (TECAN GENious Pro) at 492 nm. Results are represented as 100 wild type viability.Viral Entry AssaysA standard entry assay was performed as described previously [8]. Briefly, HCE cells were seeded at a density of 26104 in a 96well plate. Upon Bexagliflozin confluency cells were both treated with dilutions of SnO2 at [1000, 500, 250, 125, 62, 31, 0] mg/ml and infected with Castanospermine site beta-galactosidase expressing recombinant virus HSV-1 (KOS)gL86 at a multiplicity of infection equal to 10 (MOI = 10)for 6 hours at 37uC. After 6 hours cells were washed with PBS and soluble substrate o-nitrophenyl-beta-D-galactopyranoside (ONPG ImmunoPure, PIERCE,) was added. Enzymatic activity was measured by a micro-pate reader (TECAN GENious Pro) at 405 nm. An X-gal staining entry assay was also performed to confirm the effect of SnO2 treatment on HSV-1 entry as described previously [11]. Briefly, HCE cells were grown in a 6-well plate until confluent and then treated (or mock treated) with 500 mg/ml of SnO2 and infected with HSV-1 (KOS)gL86 reporter virus (MOI = 10). 6 hours post infection cells were washed with PBS and fixed with 2 formaldehyde and 0.2 glutaradehyde at room temperature for 15 minutes. Cells were washed with PBS and permeabilized with 2 mM MgCl2, 0.01 deoxycholate and 0.02 Nonidet NP-40 for 15 minutes. After washing cells with PBS cells were treated with ferricyanide buffer containing beta-galactosidase substrate X-gal. Cells were assessed by capturing images of blue cells at a 106 objective (Zeiss Axiovert 200).Plaque AssayA monolayer of HCE cells were seeded in a 6-well plate at a density of 36106 cells per well. Upon confluency cells were treated (or mock treated) with 500 ug/ml of SnO2 nanowires andTin Oxide Nanowires as Anti-HSV AgentsFigure 6. SnO2 exhibits HSV-1 binding ability. A binding assay was preformed to determine the interactions of SnO2 with K26 GFP virus. A SnO2 solution was placed.Reen fluorescent protein was fused in framed with the UL35 open reading frame generating K26GFP virus whose capsids expressTin Oxide Nanowires as Anti-HSV AgentsFigure 5. SnO2 treatment reduces glycoprotein mediated cell-to-cell fusion. Two populations of cells were generated to determine the effect of SnO2 treatment on cell fusion. Effector cells were 25033180 transfected with plasmids gB, gD, gH, gL and T7. Target cells were transfected with gD, receptor Nectin-1 and a luciferase expressing plasmid under the control of a T7 promoter. Target and Effector cells were mixed together at a 1:1 ratio. Luciferase activity was determined in the presence of firefly luciferase, allowing the measurement of relative light units (RLU). CHO-K1 cells were either mock treated or treated with SnO2. As a negative control, effector cells lacking gB were mixed with the target cells. doi:10.1371/journal.pone.0048147.gGFP [21]. Virus stocks were propagated and tittered on Vero cells and stored at 280uC.Cytotoxicity AssayTo determine the effect of SnO2 nanowires on the viability of HCE cells an MTS cytotoxicity assay was performed after 24 hours of SnO2 treatment. Briefly, HCE cells were seeded at a density of 26104 in a 96-well plate and incubated until confluent. SnO2 was then brought into suspension in MEM media at concentrations of [3000, 1500, 750, 375, 187, 93, 47, or 0] mg/ ml and added to the appropriate wells. 24 hours later the cell viability was analyzed by a chromogenic kit (CellTiter Aqueous96; Promega, Madison, WI, USA). Colorimetric detection was measured by a micro-pate reader (TECAN GENious Pro) at 492 nm. Results are represented as 100 wild type viability.Viral Entry AssaysA standard entry assay was performed as described previously [8]. Briefly, HCE cells were seeded at a density of 26104 in a 96well plate. Upon confluency cells were both treated with dilutions of SnO2 at [1000, 500, 250, 125, 62, 31, 0] mg/ml and infected with beta-galactosidase expressing recombinant virus HSV-1 (KOS)gL86 at a multiplicity of infection equal to 10 (MOI = 10)for 6 hours at 37uC. After 6 hours cells were washed with PBS and soluble substrate o-nitrophenyl-beta-D-galactopyranoside (ONPG ImmunoPure, PIERCE,) was added. Enzymatic activity was measured by a micro-pate reader (TECAN GENious Pro) at 405 nm. An X-gal staining entry assay was also performed to confirm the effect of SnO2 treatment on HSV-1 entry as described previously [11]. Briefly, HCE cells were grown in a 6-well plate until confluent and then treated (or mock treated) with 500 mg/ml of SnO2 and infected with HSV-1 (KOS)gL86 reporter virus (MOI = 10). 6 hours post infection cells were washed with PBS and fixed with 2 formaldehyde and 0.2 glutaradehyde at room temperature for 15 minutes. Cells were washed with PBS and permeabilized with 2 mM MgCl2, 0.01 deoxycholate and 0.02 Nonidet NP-40 for 15 minutes. After washing cells with PBS cells were treated with ferricyanide buffer containing beta-galactosidase substrate X-gal. Cells were assessed by capturing images of blue cells at a 106 objective (Zeiss Axiovert 200).Plaque AssayA monolayer of HCE cells were seeded in a 6-well plate at a density of 36106 cells per well. Upon confluency cells were treated (or mock treated) with 500 ug/ml of SnO2 nanowires andTin Oxide Nanowires as Anti-HSV AgentsFigure 6. SnO2 exhibits HSV-1 binding ability. A binding assay was preformed to determine the interactions of SnO2 with K26 GFP virus. A SnO2 solution was placed.